Summary of overall efficacy
| End point . | Time period . | Evaluable patients . | Response, n (%) . |
|---|---|---|---|
| ≥50% spleen-length reduction by physical examination | Up to week 24 | 33 | 14 (42.4%) |
| ≥50% spleen-length reduction by physical examination | Up to treatment termination | 33 | 15 (45.5%) |
| ≥35% reduction by MRI | Up to week 24 | 26 | 8 (30.8%) |
| ≥35% reduction by MRI | Up to treatment termination | 26 | 11 (42.3%) |
| ≥50% reduction in total symptom score from baseline | Up to week 24 | 31 | 15 (48.4%) |
| ≥50% reduction in total symptom score from baseline | Up to treatment termination | 31 | 18 (58.1%) |
| End point . | Time period . | Evaluable patients . | Response, n (%) . |
|---|---|---|---|
| ≥50% spleen-length reduction by physical examination | Up to week 24 | 33 | 14 (42.4%) |
| ≥50% spleen-length reduction by physical examination | Up to treatment termination | 33 | 15 (45.5%) |
| ≥35% reduction by MRI | Up to week 24 | 26 | 8 (30.8%) |
| ≥35% reduction by MRI | Up to treatment termination | 26 | 11 (42.3%) |
| ≥50% reduction in total symptom score from baseline | Up to week 24 | 31 | 15 (48.4%) |
| ≥50% reduction in total symptom score from baseline | Up to treatment termination | 31 | 18 (58.1%) |
Patients included in the analysis are those patients who had a nonmissing baseline measurement and postbaseline measurement at or through the time point specified. Source: supplemental Tables 5.1 and 5.6.